PURPOSE OF THE STUDY.
The authors measured levels of lipoxin A4 (LXA4) and annexin A1 (ANXA1) in children with a history of infantile wheezing. Lipoxins and annexins are classes of mediators involved in the resolution of inflammation.
Fifty-nine children with a history of wheezing with no underlying disease and 28 healthy control subjects were recruited in this Turkish study. Ages ranged from 6 to 36 months, and all children had a history of ≥3 wheezing attacks with no previous corticosteroid treatment during the preceding month.
Blood samples were taken to measure LXA4 and ANXA1 levels by using enzyme-linked immunosorbent assay. Total IgE levels and eosinophil counts were also measured.
No significant differences in total IgE levels were detected between children with wheezing and control children. LXA4 (66 ± 35 vs 120 ± 11 pg/mL; P < .05) and ANXA1 (14.45 ± 3.26 vs 16.40 ± 1.94 ng/mL; P < .05) levels were significantly lower in the wheezing group than in the control group. In the wheezing group, a significant correlation was found between the serum total IgE level and the percentage and absolute number of eosinophils (r = –0.223, P = .02). No correlation was detected between groups when LXA4 levels, ANXA1 levels, total IgE levels, and the percentage and absolute number of eosinophils were calculated (P > .05).
Serum levels of LXA4 and ANXA1, which are known to be anti-inflammatory mediators, were low in wheezy infants. Decreased synthesis may be one of the reasons for airway inflammation in these infants.
LXA4, which is expressed on leukocytes and airway epithelial cells, blocks both airway hyperresponsiveness and pulmonary inflammation. In adult studies, it has been shown that the level of LXA4 is low in patients with severe asthma. In experimental studies, ANXA1 is associated with the development of asthma. Smokers and those with inflammatory lung conditions such as cystic fibrosis and asthma have been found to have defective ANXA1 molecules. The authors in this study found that wheezing infants had lower LXA4 and ANXA1 levels, suggesting an increased susceptibility to recurring inflammatory changes in the airways. Following LXA4 and ANXA1 levels over time may be a way to help predict which children will develop childhood asthma and allow for earlier treatment interventions.
- Copyright © 2014 by the American Academy of Pediatrics